Position in SLXN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
337,500
0.0% QoQ
Ownership
6.07%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 94%
Shared 6%
None 0%
Common Shares in SLXN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Linden Advisors LP holds $8,669,084 across 8 Biotechnology names. SLXN ranks #8 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
27,426 | $8,669,084 | |
| 2 | ICU |
SeaStar Medical Holding Corp
|
218,073 | $0 | |
| 3 | MLEC |
Moolec Science SA
|
594,637 | $0 | |
| 4 | ASBP |
Aspire Biopharma Holdings, Inc.
|
899,999 | $0 | |
| 5 | TVGN |
Tevogen Inc.
|
649,999 | $0 | |
| 6 | REVB |
Revelation Biosciences, Inc.
|
337,752 | $0 | |
| 7 | LIMN |
Liminatus Pharma, Inc.
|
268,199 | $0 | |
| 8 | SLXN |
Silexion Therapeutics Corp
This page
|
337,500 | $0 |
All Filings in SLXN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 SLXNW | — | 337,500 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 SLXNW | — | 337,500 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 SLXNW | — | 337,500 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 SLXNW | — | 337,500 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 SLXNW | — | 337,500 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 SLXNW | — | 337,500 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 SLXNW | — | 337,500 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 SLXNW | — | 337,500 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||